First FDA approval for CAR-T cell therapy

The FDA formally approved the first CAR-T cell therapy for leukaemia. The treatment, which goes by the brand name Kymriah, is produced by Novartis. It will treat acute lymphocytic leukaemia (ALL), a common type of childhood cancer. Current treatments achieve remission rates of 85%. Kymriah is a new therapy for those patients who do not respond to standard treatments or who have relapsed. CAR-T cell therapies for other types of leukaemia are being developed and the treatment is currently also being explored for sold tumours.